Trastuzumab biosimilar (Outlook Therapeutics)

曲妥珠单抗生物类似药 (Outlook Therapeutics)

Report date: 2025/05/06 16:57:44

Base Information

Drug NameTrastuzumab biosimilar (Outlook Therapeutics)
Drug Alias NameONS-1050
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsColorectal NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOutlook Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOutlook Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsColorectal NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A